ACALABRUTINIB

Information current as at: 1 June 2026

PBAC meeting date: November 2021
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Calquence®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
AstraZeneca Pty Ltd
Condition/indication:
(therapeutic use)
  • Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Change to listing (–)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
November 2021 PBAC meeting
Opportunity for consumer comment:
Open 28/07/2021 and close 22/09/2021 (see PBS Website)
PBAC meeting:
Held on 03/11/2021
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
Public Summary Documents – November 2021
Case ID
a390
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19